



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2		Complete if Known	
		Application Number	09/998.250
		Filing Date	11/30/01
		First Named Inventor	DEDHAR, et al.
		Group Art Unit	1633
		Examiner Name	Unassigned
		Attorney Docket Number	KINE-001 CIP5

RECEIVED
APR 05 2002
TECH CENTER 600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
<i>rn</i>		6,001,622		Dedhar et al.	12/1999	Class 435, Subclass 194 (cited by examiner)

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
<i>rn</i>		WO	94/21781		WORLD	09/1974		
<i>↓</i>		CA	96/00760		WORLD	05/1996		
<i>↓</i>		WO	96/36642		DAVIS et al.	11/1996		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>rn</i>		DEDHAR, SHOUKAT, "Integrin Mediated Signal Transduction In Oncogenesis: An Overview," <i>Cancer and Metasis Reviews</i> (1995) Vol. 14:165-172.	
<i>rn</i>		DEDHAR and HANNIGAN, "Integrin Cytoplasmic Interactions and Bidirectional Transmembrane Signaling," <i>Current Opinion Cell Bio.</i> (1996) Vol. 8:559-657.	
		GIMOND et al., <i>Exp. Cell Res.</i> , (1995) Vol. 216:232-235. (Cited by Examiner)	
		GIVSKOV et al., Swiss Pat. 38 Accession P18954, 11/1990 (Cited by Examiner)	
		Genbank Accession Number H70160	
		Genbank Accession Number R91874 (Cited by Examiner)	
<i>rn</i>		HANNIGAN et al., "Regulation of Cell Adhesion and Anchorage Dependent Growth By A New Beta1 Integrin Linked Protein Kinase," <i>Nature</i> (1996) Vol. 379:91-96.	
		HANNIGAN et al., "Overexpression of A Novel Integrin Linked Kinase (ILK) Induces A Transformed Phenotype and Cyclin D1 Expression," <i>Molecular Biology of the Cell</i> (November 1995) Vol. 6:2244 XP000673935.	
<i>↓</i>		HANNIGAN et al., "Cloning of A Novel Protein Kinase Associated With Beta 1 Integrin Cytoplasmic Tails," <i>86th Annual Meeting of the American Association for Cancer Research</i> (March 1995) P:361. XP000673939.	
Examiner Signature	<i>[Signature]</i>		Date Considered

5/30/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
Sheet		2	of	2	Application Number 09/998,250 Filing Date 11/30/01 First Named Inventor DEDHAR, et al. Group Art Unit 1633 Examiner Name Unassigned Attorney Docket Number KINE-001 CIP5

	KAPPEL, CATHERINE A. et al., (1992) <i>Current Opinion in Biotechnology</i> Vol. 3:548-553. (Cited by Examiner)	
	LIN, TSUNG H. et al., "Integrin-Mediated Tyrosine Phosphorylation and Cytokine Mesage Induction in Monocytic Cells," <i>The Journal of Biological Chemistry</i> (July 7, 1995) Vol. 270, No. (27):16189-16197.	
	JACQ et al., (1994) <i>Cell</i> Vol. 79, No. (1):107-117. (Cited by Examiner)	
	MIYAMOTO, SHINGO et al., "Synergistic Roles for Receptor Occupancy and Aggregation in Integrin Transmembrane Function," <i>Science</i> (Feb. 10, 1995) Vol. 267:883-885.	
	PALMITER er al., (Nov. 1983) <i>Science</i> Vol. 222:809-814.	
	PURSEL, V.G. et al., (1990) <i>J. Reprod. Fert., Suppl.</i> Vol. 40:235-245.	
	MORINO et al., "Matrix-Integrin Interaction Activates the Mitogen Activated Protein Kinase p44erk, 1 and p42erk-2," <i>J. Biological Chemistry</i> (1995) Vol. 270:269-273.	
	ROSALES, CARLOS et al., "Signal Transduction By Cell Adhesion Receptors," <i>Biochimica et Biophysica Acta</i> (1995) Vol. 1242:77-98.	
	RUDINGER, J. et al., Peptide Hormones, Edited by Parsons, University Park Press, Baltimore, p. 1-7 (Cited by Examiner)	
	LIPFERT. et al., (1992) <i>J. Cell Biol.</i> Vol. 199:905-912	

Examiner Signature		Date Considered	5/30/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO-THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.